Skip to content
Men Under Microscope – Lifestyle
Home
Sample Page
Author:
Skyhawk Therapeutics
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease
June 1, 2026
/C O R R E C T I O N — Skyhawk Therapeutics/
May 18, 2026
Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule
May 18, 2026
Skyhawk Therapeutics Announces its Founding Scientific Advisory Board Chairman Receives the American Cancer Society’s 2026 Medal of Honor
March 30, 2026
Skyhawk Therapeutics Appoints Aaron Deves as Chief Commercial Officer to Lead Commercialization of SKY-0515 for Huntington’s Disease
March 10, 2026